“
On July 18, 2025, Hangzhou - "Fuleke" jointly organized by Lindmik Pharmaceutical (Suzhou) Co., Ltd. and Hangzhou Longyu Biopharmaceutical Technology Co., Ltd ® The "Flurbiprofen gel Paste Product Marketing Meeting" was held in Hangzhou. The event brought together industry partners, channel representatives, and media guests to witness the innovative achievements in the field of topical anti-inflammatory and analgesic drugs. Fuleke ® The listing of flurbiprofen gel plaster marks a new stage of in-depth cooperation between Luming Pharmaceutical and its agents in the field of chronic pain management, providing patients with more high-quality and accessible treatment options.
Empowered by Innovative Technology, Reshaping New Standards for Topical Anti-inflammatory Treatment
Fuleke ® Flurbiprofen gel ointment adopts the internationally leading hydrogel transdermal absorption technology, and achieves local high efficiency anti-inflammatory and analgesic effect by precisely controlling drug release.
The core advantages of the product include:
Safe and Efficient: Avoiding the first pass effect of oral administration, significantly reducing the burden on the gastrointestinal tract and liver and kidney, especially suitable for the elderly and long-term medication patients.
Durable Comfort: Apply twice a day to release the drug effect for 12 hours. The hydrogel matrix is skin friendly and breathable to improve patient compliance.Data Support: Based on clinical trials, the product's efficacy is bioequivalent to the original drug, with a low incidence of adverse reactions and clinically validated safety.
Strong Collaboration to Build an Omnichannel Service Network
Through strategic cooperation, Lindmik Pharmaceutical and Hangzhou Longyu Biomedical Technology Co., Ltd. will rely on Longyu Biotechnology's deep channel layout in Zhejiang and surrounding provinces, combined with Lindmik Pharmaceutical's innovative research and development capabilities, to jointly promote product market coverage.
Channel Sinking: By covering grassroots medical institutions through a network of agents, we aim to improve product accessibility, especially for county-level markets with high incidence of osteoarthritis.
Patient Education: Jointly carry out the "Chronic Pain Management Science Popularization Action" to popularize the correct use of topical anti-inflammatory drugs through a combination of online and offline methods.
Quality Assurance: While the price is lower than the original research drug, Lindmik Pharmaceutical strictly follows GMP standards in production, ensuring that the key indicators such as transdermal absorption rate and adhesion of each patch are consistent with the original drug, and quickly reaching more patients with a "high-quality and cost-effective" strategy.
Adhere to the Bottom Line of Compliance and Convey the Concept of Scientific Drug Use
Lindmik Pharmaceutical always regards compliance as the lifeline of the enterprise, and strictly adheres to the Drug Administration Law, Advertising Law, and relevant compliance guidelines in product promotion, eliminating behaviors such as exaggerating efficacy and false advertising. All promotional content has been registered and reviewed by provincial drug regulatory departments to ensure that drug information is conveyed in a scientific and objective manner.
About Longyu Biotechnology
Hangzhou Longyu Biopharmaceutical Technology Co., Ltd. has been deeply involved in the medical market in Zhejiang Province for more than 10 years. It is a pioneer in refined terminal promotion in Zhejiang Province, and has formed a global innovative medical device research, development, production, and sales business mainly focused on professional drug agency promotion and omni channel marketing, and has entered the field of sleep breathing. The company has established strategic partnerships with multiple top 100 pharmaceutical companies and listed companies, and its main products have a leading market share in the same category.
Lindmik Pharmaceutical (Suzhou) Co., Ltd. focuses on the field of transdermal formulations, with the mission of "innovation for the people", and builds a full industry chain system from research and development to commercialization. Roledi under its umbrella ® Loxoprofen sodium gel paste, Fu Le Ke ® Flurbiprofen gel paste and other products are recognized by the market with their excellent quality.
From January 14, 2025, Roledi ® After the production batch number of loxoprofen sodium gel paste was obtained, Shanghai, Jiangsu, Guangdong and other provinces held marketing promotion conferences in succession. The atmosphere was warm. Through visual demonstration and empirical case sharing, the product characteristics and application scenarios were systematically introduced, and its academic nature was recognized by the participants.
In the future, Lindmik Pharmaceutical and more partners will continue to deepen cooperation, with innovative products as the cornerstone and compliance services as the guarantee, to jointly promote the development of chronic pain management in China and make health within reach.
Lindmik Pharmaceutical(Suzhou)Co.,Ltd is a high-tech pharmaceutical enterprise focusing on the research and development, production and sales of innovative pharmaceutical preparations.Equipped with a number of its own innovative R&D platform of dosage forms, including the transdermal drug delivery system, and at the same time, actively introducing the world’s leading nano-based drug delivery, microspheres drug delivery and other cutting-edge pharmaceutical technologies by means of “license in”, the company is a new rapidly developing company pharmaceutical companies that catches people’s eyes.
12th Floor, Building 5, Tianyun Plaza, 111 Wusongjiang Avenue, Guoxiang Street, Wuzhong District, Suzhou City
0512-66020899
0512-66022699
215124
